Suppr超能文献

白内障手术中散瞳插入剂和前房内注射与散瞳眼药水的比较:对照研究

Mydriatic insert and intracameral injections compared with mydriatic eyedrops in cataract surgery: controlled studies.

作者信息

Behndig Anders, Korobelnik Jean-François

机构信息

From the Department of Clinical Sciences/Ophthalmology (Behndig), Umeå University Hospital, Sweden, and Service d'ophtalmologie, Centre Hospitalier Universitaire de Bordeaux, Institut de Santé Publique, d'Epidémiologie et de Développement, and the Institut National de la Santé et de la Recherche Médicale U897-Epidemiologie-Biostatistique (Korobelnik), Bordeaux, France.

From the Department of Clinical Sciences/Ophthalmology (Behndig), Umeå University Hospital, Sweden, and Service d'ophtalmologie, Centre Hospitalier Universitaire de Bordeaux, Institut de Santé Publique, d'Epidémiologie et de Développement, and the Institut National de la Santé et de la Recherche Médicale U897-Epidemiologie-Biostatistique (Korobelnik), Bordeaux, France.

出版信息

J Cataract Refract Surg. 2015 Jul;41(7):1503-19. doi: 10.1016/j.jcrs.2014.12.050.

Abstract

UNLABELLED

Mydriatic eyedrops are the standard method for pupil dilation in cataract surgery, but their limitations have prompted a search for alternative techniques. Two alternatives-an ophthalmic insert containing phenylephrine and tropicamide and intracameral injections of various combinations of lidocaine, cyclopentolate, and phenylephrine, with or without epinephrine in the irrigating solution-have been assessed in prospective controlled studies, including randomized controlled trials (RCTs). We reviewed the safety and efficacy of mydriatic ophthalmic inserts and intracameral mydriatic injections compared with the safety and efficacy of mydriatic eyedrops using a systematic PubMed search (1963 to 2014). We identified 9 prospective studies (7 RCTs, 637 patients) of the mydriatic ophthalmic insert and 15 prospective studies (14 RCTs, 1020 patients) of intracameral mydriatic injections; 7 of the RCTs compared intracameral mydriatic injections and mydriatic eyedrops and 7 RCTs studied the optimum intracameral mydriatic injection protocol. The latter showed that a lidocaine and phenylephrine-based solution, without irrigating epinephrine, was optimum for intracameral mydriatic injections. The mydriatic ophthalmic insert and intracameral mydriatic injections were consistently shown to be safe and as effective as mydriatic eyedrops. Each method has distinct advantages and limitations.

FINANCIAL DISCLOSURE

Dr. Behndig has received fees from Théa Pharma GmbH as a member of the European Team for the Prophylaxis of Infection in Cataract Surgery group. Dr. Korobelnik has received consultancy fees from Alcon Surgical, Inc.; Allergan, Inc.; Alimera, Inc.; Bayer HealthCare AG; Carl Zeiss Meditec AG; Novartis Corp.; Roche Innovatis AG; and Théa Pharma GmbH.

摘要

未标注

散瞳眼药水是白内障手术中瞳孔散大的标准方法,但其局限性促使人们寻找替代技术。两种替代方法——一种含有去氧肾上腺素和托吡卡胺的眼科插入物以及前房内注射利多卡因、环喷托酯和去氧肾上腺素的各种组合,冲洗液中含或不含肾上腺素——已在前瞻性对照研究中进行了评估,包括随机对照试验(RCT)。我们通过系统检索PubMed(1963年至2014年),回顾了散瞳眼科插入物和前房内散瞳注射与散瞳眼药水相比的安全性和有效性。我们确定了9项关于散瞳眼科插入物的前瞻性研究(7项RCT,637例患者)和15项关于前房内散瞳注射的前瞻性研究(14项RCT,1020例患者);其中7项RCT比较了前房内散瞳注射和散瞳眼药水,7项RCT研究了最佳的前房内散瞳注射方案。后者表明,一种不含冲洗肾上腺素的基于利多卡因和去氧肾上腺素的溶液是前房内散瞳注射的最佳选择。散瞳眼科插入物和前房内散瞳注射一直被证明是安全的,并且与散瞳眼药水一样有效。每种方法都有独特的优点和局限性。

财务披露

Behndig博士作为白内障手术感染预防欧洲团队的成员,已从Thea Pharma GmbH获得报酬。Korobelnik博士已从爱尔康外科公司、爱力根公司、Alimera公司、拜耳医疗保健公司、卡尔蔡司医疗技术公司、诺华公司、罗氏创新公司和Thea Pharma GmbH获得咨询费。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验